Daniel Bazarko - Jul 21, 2021 Form 4 Insider Report for ALEXION PHARMACEUTICALS, INC. (ALXN)

Signature
/s/ Douglas Barry, Attorney-in-Fact for Daniel Bazarko
Stock symbol
ALXN
Transactions as of
Jul 21, 2021
Transactions value $
-$2,835,424
Form type
4
Date filed
7/23/2021, 04:39 PM
Previous filing
Jul 16, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALXN Common Stock, par value $.0001 per share Disposed to Issuer $0 -60.2K -100% $0.00* 0 Jul 21, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALXN Option to Purchase Common Stock Disposed to Issuer -$696K -5.3K -100% $131.25 0 Jul 21, 2021 Common Stock 5.3K $131.25 Direct F2
transaction ALXN Option to Purchase Common Stock Disposed to Issuer -$904K -5.11K -100% $176.80 0 Jul 21, 2021 Common Stock 5.11K $176.80 Direct F2
transaction ALXN Option to Purchase Common Stock Disposed to Issuer -$711K -3.94K -100% $180.37 0 Jul 21, 2021 Common Stock 3.94K $180.37 Direct F2
transaction ALXN Option to Purchase Common Stock Disposed to Issuer -$525K -2.91K -100% $180.28 0 Jul 21, 2021 Common Stock 2.91K $180.28 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Daniel Bazarko is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration").
F2 Upon the First Effective Time, these options were cancelled and converted into the right to receive the product obtained by multiplying (A) the excess, if any, of the value of the Merger Consideration over the exercise price per share of the Alexion common stock subject to such options immediately prior to the First Effective Time by (B) the number of shares of Alexion common stock subject to such option immediately prior to the First Effective Time by (ii) the value of the Merger Consideration.